SlateStone Wealth LLC Lowers Position in AbbVie Inc. $ABBV

SlateStone Wealth LLC lowered its position in shares of AbbVie Inc. (NYSE:ABBV) by 6.5% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 36,607 shares of the company’s stock after selling 2,563 shares during the period. SlateStone Wealth LLC’s holdings in AbbVie were worth $8,476,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in shares of AbbVie by 1.9% in the 2nd quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock worth $32,910,186,000 after purchasing an additional 3,380,842 shares in the last quarter. Geode Capital Management LLC increased its holdings in AbbVie by 2.4% in the 2nd quarter. Geode Capital Management LLC now owns 39,178,351 shares of the company’s stock worth $7,240,169,000 after buying an additional 924,761 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in AbbVie by 6.0% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 26,783,329 shares of the company’s stock worth $4,970,848,000 after buying an additional 1,517,222 shares during the last quarter. Norges Bank purchased a new stake in shares of AbbVie during the 2nd quarter valued at about $4,288,200,000. Finally, Raymond James Financial Inc. grew its stake in shares of AbbVie by 41.8% in the second quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock worth $1,733,222,000 after acquiring an additional 2,753,312 shares during the period. 70.23% of the stock is currently owned by institutional investors.

AbbVie Trading Up 0.4%

NYSE:ABBV opened at $220.00 on Friday. The stock has a 50-day moving average price of $223.81 and a 200 day moving average price of $219.14. The stock has a market capitalization of $388.83 billion, a P/E ratio of 92.95, a P/E/G ratio of 0.89 and a beta of 0.35. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.65 by $0.06. The business had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The firm’s revenue for the quarter was up 10.0% compared to the same quarter last year. During the same period in the prior year, the company posted $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, research analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Morgan Stanley raised its price target to $270 and kept an overweight rating, signaling analyst confidence that AbbVie’s immunology momentum supports meaningful upside. Read More.
• Positive Sentiment: AbbVie beat Q4 estimates and issued FY‑2026 adjusted EPS guidance above Wall Street consensus, driven by strong Skyrizi and Rinvoq sales — a central bullish thesis for earnings growth and cash generation. Read More. Read More.
• Neutral Sentiment: MarketBeat and some commentators frame the post‑earnings pullback as a buying opportunity, noting heavy institutional ownership and long‑term dividend/cash‑flow support. This view suggests the sell‑off may be technical rather than fundamental. Read More.
• Neutral Sentiment: Some sell‑side and independent analysts (Evercore, others) remain bullish on AbbVie’s immunology momentum and neurology upside, supporting continued accumulation despite near‑term noise. Read More.
• Negative Sentiment: Shares initially gapped down on the earnings reaction — investors focused on weaker Q1/near‑term guidance (Q1 EPS guide below street consensus and lighter revenue outlook), which overshadowed the headline beat. Read More.
• Negative Sentiment: Some analysts and commentaries flagged concentration risk: while Skyrizi and Rinvoq are driving growth, weaknesses in aesthetics and oncology and questions about growth beyond immunology (and reliance on M&A/IPR&D) are prompting investor skepticism. Read More.
• Negative Sentiment: Strategic moves (e.g., Rinvoq’s expanded indications like vitiligo) raise valuation and execution questions for some investors — potential upside if successful, but added near‑term uncertainty. Read More.

Analysts Set New Price Targets

ABBV has been the subject of a number of research reports. Guggenheim boosted their target price on shares of AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a research note on Monday, October 20th. Morgan Stanley increased their target price on AbbVie from $269.00 to $270.00 and gave the company an “overweight” rating in a report on Thursday. Hsbc Global Res upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, December 10th. UBS Group reduced their price target on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating for the company in a research report on Thursday. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $258.00 price objective on shares of AbbVie in a report on Thursday, January 15th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $251.00.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.